Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

FUJIREBIO

Fujirebio is a global leader in the field of IVD testing with more than 50 years’ experience in the conception, devel... read more Featured Products: More products

Download Mobile App




APOE Gene Influences Alzheimer's Symptoms, Biomarkers in Down Syndrome

By LabMedica International staff writers
Posted on 22 Jul 2021
Individuals with Down syndrome (DS) constitute a population at ultrahigh risk of developing Alzheimer disease (AD) because of trisomy of chromosome 21, which harbors the amyloid precursor protein (APP) gene.

The apolipoprotein E (APOE) ε4 allele is the most established genetic risk factor for sporadic AD and has been consistently associated with earlier AD symptoms and pathology in the general population. More...
A similar disease-accelerating feature might exist in DS given that studies in this population have reported that ɛ4 allele carriers show an earlier onset of clinical symptoms and greater amyloid burden than non-carriers.

An international team of Neurologists and their colleagues led by those at the Hospital of the Holy Cross and Saint Paul (Barcelona, Spain) recruited adults with DS. In Barcelona, Spain, adults with DS were recruited from a population-based health plan that was developed for the screening of AD from which the Down Alzheimer Barcelona Neuroimaging Initiative cohort. In the UK, participants were selected from a convenience sample that was recruited from services for people with intellectual disabilities in England and Scotland. Of 464 participants, 97 were APOE ε4 carriers and 367 were non-carriers.

DNA was extracted from peripheral blood by technicians who were blinded to clinical and biomarker data, and APOE genotyping was determined by polymerase chain reaction amplification. Participants were dichotomized according to the presence of at least one ɛ4 allele. Plasma levels of phosphorylated tau 181 (pTau181) and neurofilament light chain (NfL) were measured using single molecule array technology (Simoa; Quanterix, Billerica, MA, USA). The CSF levels of amyloid-β peptide 1-40 (Aβ1-40), Aβ1-42, pTau181, and total tau were quantified using a fully automated platform (Lumipulse; Fujirebio, Malvern, PA, USA). The CSF NfL levels were measured with enzyme-linked immunosorbent assay (NF-Light Assay; UmanDiagnostics, Umeå, Sweden).

The investigators reported that no differences between the two groups were found by age or sex (51 male carriers [52.6%] versus 199 male non-carriers [54.2%]). APOE ɛ4 allele carriers compared with non-carriers presented with AD symptoms at a younger age and showed earlier cognitive decline. Locally estimated scatterplot smoothing curves further showed between-group differences in biomarker trajectories with age as reflected by non-overlapping CIs. Specifically, carriers showed lower levels of the CSF Aβ1-42 to Aβ1-40 ratio until age 40 years, earlier increases in amyloid PET and plasma pTau181, and earlier loss of cortical metabolism and hippocampal volume. No differences were found in NfL biomarkers or CSF total tau and pTau181. Voxelwise analyses showed lower metabolism in subcortical and parieto-occipital structures and lower medial temporal volume in APOE ɛ4 allele carriers.

The authors concluded that APOE ɛ4 allele carriers (compared with non-carriers) showed an earlier decline in episodic memory, earlier clinical diagnosis of symptomatic AD, earlier changes in AD biomarkers, and differences in the pattern of neurodegeneration. These findings demonstrated that the APOE ɛ4 allele can modulate both the clinical expression and biomarkers of AD in a genetic form of the disease, such as in DS, and emphasize the importance of the APOE genotype for future clinical trials in DS. The study was published on July 6, 2021 in the journal JAMA Neurology.

Related Links:
Hospital of the Holy Cross and Saint Paul
Quanterix
Fujirebio
UmanDiagnostics



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Microbiology Laboratory Automation Solution
BD Kiestra™ ReadA+BarcodA
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers combined a blood-based biomarker of Alzheimer’s disease with age, sex, and genetic risk to estimate future cognitive impairment risk in asymptomatic adults (Image Credit: Adobe Stock)

Blood Biomarker Model May Help Estimate Five- and 10-Year Cognitive Impairment Risk

Estimating future cognitive impairment risk remains challenging in cognitively healthy adults, particularly when biomarker findings are reduced to simple positive or negative results. Because mild cognitive... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Malaria is caused by Plasmodium parasites, primarily transmitted through the bites of infected female Anopheles mosquitoes (Image Credit: Adobe Stock)

Complete Malaria Genomes Could Improve Species Identification and Surveillance

Malaria remains a major global health challenge, with an estimated 282 million cases and 610,000 deaths worldwide in 2024. Although most research has focused on Plasmodium falciparum, Plasmodium ovale... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.